During the recent session, Atossa Therapeutics Inc (NASDAQ:ATOS)’s traded shares were 0.43 million, with the beta value of the company hitting 1.20. At the last check today, the stock’s price was $1.43, reflecting an intraday loss of -2.05% or -$0.03. The 52-week high for the ATOS share is $2.31, that puts it down -61.54 from that peak though still a striking 56.64% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $179.84M, and the average intraday trading volume over the past 10 days was 0.57 million shares, and the average trade volume was 999.69K shares over the past three months.
Atossa Therapeutics Inc (ATOS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATOS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Atossa Therapeutics Inc (NASDAQ:ATOS) trade information
Atossa Therapeutics Inc (ATOS) registered a -2.05% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.05% in intraday trading to $1.43, hitting a weekly high. The stock’s 5-day price performance is -5.92%, and it has moved by 2.88% in 30 days. Based on these gigs, the overall price performance for the year is 85.71%. The short interest in Atossa Therapeutics Inc (NASDAQ:ATOS) is 12.9 million shares and it means that shorts have 21.85 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 71.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, ATOS is trading at a discount of -249.65% off the target high and -249.65% off the low.
Atossa Therapeutics Inc (ATOS) estimates and forecasts
Statistics show that Atossa Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Atossa Therapeutics Inc (ATOS) shares have gone down -14.88% during the last six months, with a year-to-date growth rate less than the industry average at 8.33% against 12.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -20.00% this quarter and then jump 33.30% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.61%. While earnings are projected to return 7.29% in 2024.
ATOS Dividends
Atossa Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Atossa Therapeutics Inc (NASDAQ:ATOS)’s Major holders
Atossa Therapeutics Inc insiders own 0.06% of total outstanding shares while institutional holders control 27.41%, with the float percentage being 27.43%. BLACKROCK INC. is the largest shareholder of the company, while 100.0 institutions own stock in it. As of 2024-06-30, the company held over 9.2 million shares (or 7.3389% of all shares), a total value of $10.94 million in shares.
The next largest institutional holding, with 6.49 million shares, is of VANGUARD GROUP INC’s that is approximately 5.1755% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.72 million.
